Articles related to BREAST CANCER

Healthcare providers demonstrate different treatment approaches based on patient demographics and perceived medical knowledge, requiring systematic advocacy training.

Previous research on omega-6 fatty acids has produced mixed results and often lacked clarity on how these fats affect cancer risk… this research is focused on clearing up those uncertainties.

A comprehensive analysis of 176,601 cancer cases demonstrates that long-acting reversible contraceptives offer a cancer risk profile comparable to oral contraceptives, with data showing a 20-30% reduction in gynecologic cancer risk and a modest increase in breast cancer risk that returns to baseline after cessation.

The combination of imlunestrant plus abemaciclib demonstrated significant progression-free survival benefit across all subgroups, including patients with prior CDK4/6 inhibitor use and those with visceral metastases.

In a cohort of 601 women aged ≥65 years with low-risk breast cancer treated without radiotherapy, the 10-year local recurrence rate was 5.5%, with only 0.5% breast cancer-specific mortality.

Latest clinical trial data suggests active monitoring may be a viable alternative to standard treatment for select low-risk DCIS patients, with comparable quality-of-life outcomes.